Depth of Response and Early Tumor Shrinkage for Predicting Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab

BACKGROUND: To evaluate whether the depth of response (DepRe) and early tumor shrinkage (ETS) are predictive factors of clinical outcomes in HER2-positive metastatic breast cancer (mBC) patients treated with trastuzumab. METHODS: We performed a retrospective study of 100 HER2-positive mBC patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Che, Yi-Qun, Zhang, Yue, Ou, Kai-Ping, Wang, Di, Shen, Di, Liu, Hui-Ying, Luo, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502405/
https://www.ncbi.nlm.nih.gov/pubmed/32982445
http://dx.doi.org/10.2147/CMAR.S269067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502405/
https://www.ncbi.nlm.nih.gov/pubmed/32982445
http://dx.doi.org/10.2147/CMAR.S269067

Ejemplares similares